• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·688075.SS
Share

Assure Tech Stocks

CN¥ 29.88Last Updated 14.10.2026

Issuer Rating

3/7
Performance

Modest

Risk

Moderate

Recommendation

Sell

Market Cap

CN¥ 586.60M

CN¥ 29.88
Key Takeaways

Risk factor

Very vulnerable to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Assure Tech (Hangzhou) Co., Ltd. engages in the research and development, production, and sale of vitro diagnostic reagents, and instruments in China. It is also involved in POCT and plastic product manufacturing; online sales; pharmaceutical sales; and medical testing. In addition, the company offers drug of abuse, infectious disease, fertility, cardiac marker, tumor marker, allergen, and veterinary tests, as well as Biochemistry, chronic disease monitoring systems, and reader and analyzers. Further, it offers infectious disease, fertility, fecal occult blood, and vaginal pH tests. Assure Tech (Hangzhou) Co., Ltd. was founded in 2008 and is based in Hangzhou, China

Company Valuation

Greatly overvalued
1/7

Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBI

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

14.10.2026 13:31

A key supplier of machines for manufacturing AI chips can't keep up with demand. What about the stock?

14.10.2026 12:41

"All the Money in the World": Nebius's Competitor Aims to Attract Insurers' Capital for AI

14.10.2026 11:28

Retail Investors Have Returned to Betting on AI Amid a Downturn in the Chip Industry — Citadel

14.10.2026 10:34

Top Stories This Morning: Anthropic Warns of a New Threat; Luxury Market Loses $350 Billion

14.10.2026 09:55

What to Watch for in a "Bear" Bond Market: Ray Dalio's Rules

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026